Abbott

Abbott acquires OptiMedica

Monday, August 19, 2013 02:10 PM

Abbott has acquired OptiMedica, a privately-held, Silicon Valley-based ophthalmic device company.

More... »

InnovoCommerce, SAFE-BioPharma collaborate

Friday, June 28, 2013 02:02 PM

The global SAFE-BioPharma digital identity and signature standard is being incorporated into the InnovoCommerce eClinical product suite used by pharmaceutical companies for their enterprise and investigator portal initiatives. InnovoCommerce is a source of eClinical collaboration products and solutions. It also has joined SAFE-BioPharma Association’s Vendor Partner program.

More... »

Astellas Pharma joins SAFE-BioPharma

Friday, June 21, 2013 01:21 PM

Astellas Pharma has joined the SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the global SAFE-BioPharma digital identity and signature standard. As a member, Astellas is able to utilize the SAFE-BioPharma standard. It is the first Japanese pharmaceutical company to become a member.

More... »

Abbott initiates trial to evaluate Absorb BVS

Thursday, June 13, 2013 12:00 PM

Abbott has announced the initiation of the Absorb Japan randomized, controlled clinical trial to evaluate the Absorb Bioresorbable Vascular Scaffold (BVS) in patients with coronary artery disease (CAD), the most common form of heart disease. The results of this trial will support regulatory filings with the Japanese Pharmaceutical and Medical Devices Agency (PMDA) for approval of Absorb BVS in Japan.

More... »

JDRF appoints David E. Wheadon as executive vice president of research and advocacy

Thursday, May 9, 2013 12:04 PM

Juvenile Diabetes Research Foundation (JDRF), a global organization funding type 1 diabetes (T1D) research, has appointed David E. Wheadon, M.D., as its new executive vice president of research and advocacy.

More... »

David A. Dodd appointed president and CEO of Aeterna Zentaris

Friday, April 26, 2013 03:05 PM

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

More... »

PPD appoints Jay Dixon as vice president, global quality and compliance

Tuesday, March 26, 2013 08:00 AM

Pharmaceutical Product Development (PPD), a global CRO, has appointed Jay Dixon as senior vice president, global quality and compliance. Dixon’s expertise will enhance PPD’s ability to deliver industry-leading drug development services and high-quality data across the full spectrum of the research and development life cycle.

More... »

Abbott, Janssen, Pharmacyclics to develop companion test for leukemia therapy

Friday, February 22, 2013 11:16 AM

Global healthcare company Abbott has formed a collaboration with Janssen Biotech and Pharmacyclics, a biopharmaceutical company based in Sunnyvale, Calif., to explore the benefits of Abbott's proprietary FISH (fluorescence in situ hybridization) technology for use in developing a molecular companion diagnostic test to identify patients with a genetic subtype of chronic lymphocytic leukemia (CLL), the most common form of adult leukemia.

More... »

Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »

Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »